



NDA 21-067

Schering Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033

Attention: Michael Belman
Associate Director and Liaison, Global Regulatory Affairs

Dear Mr. Belman:

Please refer to your new drug application (NDA) dated November 30, 1998, received December 1, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Asmanex® Twisthaler® 220mcg (mometasone furoate inhalation powder).

We acknowledge receipt of your submissions dated September 29, November 15, and December 14, 2004, and February 1 and March 17, 2005.

The September 29, 2004, submission constituted a complete response to our May 17, 2004, action letter.

This new drug application provides for the use of Asmanex® Twisthaler® 220mcg (mometasone furoate inhalation powder) for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older and treatment of asthma patients who require oral corticosteroid therapy, where adding Asmanex® Twisthaler® therapy may reduce or eliminate the need for oral corticosteroids.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions indicated in the enclosed labeling.

The final printed labeling (FPL) must be identical to, except for including the revisions indicated, the enclosed labeling (text for the package insert, text for Patient's Instructions for Use) and submitted labeling (immediate container and carton labels submitted November 15, 2004). These revisions are terms of the NDA approval. Marketing the product before making the revisions, exactly as stated, in the product's labeling may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-067.**" Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for ages 0 to 3 years and deferring pediatric studies for ages 4 to 11 years for this application.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required post-marketing study commitments. The status of these post-marketing studies shall be reported annually according to 21 CFR 314.81. These commitments are listed below.

1. Deferred pediatric study (ies) under PREA for the maintenance treatment of asthma as prophylactic therapy in patients 4 to 11 years of age.

Final Report Submission: April 1, 2007

Submit final study reports to this NDA. For administrative purposes, all submissions related to this pediatric post-marketing study commitment must be clearly designated "**Required Pediatric Study Commitments.**"

Submit clinical protocols to your IND for this product. Submit non-clinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these post-marketing study commitments must be prominently labeled "**Post-marketing Study Protocol**", "**Post-marketing Study Final Report**," or "**Post-marketing Study Correspondence.**"

We remind you of the agreements made in your submission dated February 1, 2005. These agreements are listed below.

1. Submit a prior approval supplement containing all pertinent supportive documentation for (b)(4) (b)(4) for the drug product.
2. Re-evaluate the (b)(4) acceptance criteria after one year of commercial exp-----
3. Re-evaluate the specifications for resistance to flow-by pressure drop after one year of commercial production experience.
4. Commence within three (3) months of approval, post-approval studies to determine the underlying factors leading to the shift in the (b)(4) stage grouping deposition that is seen when comparing batches prepared (b)(4) in 2002 with those recently made in 2004, i.e., increase in Group I and decrease in Group II and III deposition. You agree to a projected completion date of no more than twelve (12) months.

5. Submit three copies of an updated methods validation package containing the following information: a). composition of the drug product formulation; b). acceptance criteria and methods for the drug substance; c). acceptance criteria and methods for the drug product; d). supporting validation data for drug substance and drug product methods; e). a list of available samples with their respective sample numbers; f). analytical results for available samples. It is requested that these be submitted within a reasonably short time after approval (e.g., within 3 months).

We have not completed validation of the regulatory methods. However, we expect your continued cooperation to resolve any problems that may be identified.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Pulmonary and Allergy Drug Products and two copies of both the promotional materials and the package insert(s) directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Lori Garcia, Regulatory Project Manager, at (301) 827-5580.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, M.D., Ph.D.
Director
Division of Pulmonary and Allergy Drug Products, HFD-570
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosure

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Badrul Chowdhury
3/30/05 03:56:59 PM